Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development

Hepatology

Volumn 48, Issue 2, 2008, Pages 487-496

  Marhenke, Silke ^a   Lamlé, Jutta ^a   Buitrago Molina, Laura Elisa ^a   Cañón, José Manuel Fernández ^b   Geffers, Robert ^c   Finegold, Milton ^d   Sporn, Michael ^f   Yamamoto, Masayuki ^g   Manns, Michael P ^a   Grompe, Markus ^e   Vogel, Arndt ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LEÓN   (Spain)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f DARTMOUTH MEDICAL SCHOOL   (United States)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; DNA; FUMARYLACETOACETASE; GLUTATHIONE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE ACTIVATION; GENE FUNCTION; HEPATITIS; LIVER CARCINOGENESIS; LIVER FIBROSIS; LIVER INJURY; LIVER TUMOR; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR PROMOTION; TYROSINEMIA;

ANIMALS; CYCLOHEXANONES; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HEPATITIS; HYDROLASES; IMIDAZOLES; LIVER; LIVER CIRRHOSIS; LIVER FAILURE; LIVER NEOPLASMS; METABOLIC DETOXICATION, DRUG; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; NITROBENZOATES; OLEANOLIC ACID; OXIDATIVE STRESS; TYROSINEMIAS;

EID: 49649101835     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22391     Document Type: Article

References (30)

1. Grompe M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis 2001;21:563-571.
2. Jorquera R, Tanguay RM. The mutagenicity of the tyrosine metabolite, fumarylacecoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 1997;232:42-48.
3. Dieter MZ, Freshwater SL, Miller ML, Shertzer HG, Dalton TP, Nebert DW. Pharmacological rescue of the 14CoS/14CoS mouse: Hepatocyte apoptosis is likely caused by endogenous oxidative stress. Free Radic Biol Med 2003;35:351-367.
4. Russo P, O'Regan S. Visceral pathology of hereditary tyrosinernia type I. Am J Hum Genet 1990;47:317-324.
5. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: Long-term outcome in French patients. J Inherit Metab Dis 2008;31:81-87.
6. van Spronsen FJ, Bijleveld CM, van Maidegern BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005;40:90-93.
7. Grompe M, Al-Dhalimy M, Finegold M, On CN, Burlingame T, Kennaway NG, et al. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 1993;7:2298-2307.
8. Grompe M, Lindstedt S, al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos CA, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995; 10:453-460.
9. Al-Dhalimy M, Overturf K, Finegold M, Grompe M. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary Eyrosinemia type I. Mol Genet Metab 2002;75:38-45.
10. Vogel A, van Den Berg IE, Al-Dhalimy M, Groopman J, Ou CN, Ryabinina O, et al. Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death. HEPATOLOGY 2004;39:433-443.
11. Orejuela D, Jorquera. R, Bergeron A, Finegold MJ, Tanguay RM. Hepatic stress in hereditary cyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah(-/-) knockout mice model. J Hepatol 2008;48:308-317.
12. Moi P, Chan K, Asunis I, Cao A, Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 1994;91:9926-9930.
13. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen. Proc Natl Acad Sci U S A 2001;98:4611-4616.
14. Langlois C, Jorquera R, Finegold M, Shroads AL, Stacpoole PW, Tanguay RM. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1. Biochem Pharmacol 2006;71:1648-1661.
15. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys; Res Commun 1997;236:313-322.
16. Bergeron A, Jorquera R, Orejuela D, Tanguay RM. Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I. J Biol Chem 2006;281:5329-5334.
17. Willenbring H, Sharma AD, Vogel A, Lee AY, Rothfuss A, Wang Z, et al. Loss of p2l permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell 2008. (In press.)
18. Liby K, Hock T, Yore MM, Suh N, Place AE, Risingsong R, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005; 65:4789-4798.
19. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-369.
20. Dehner LP, Snover DC, Sharp HL, Ascher N, Nakhleh R, Day DL. Hereditary tyrosinemia type I (chronic form): Pathologic findings in the liver. Hum Pathol 1989;20:149-158.
21. Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaptowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gascroenterology 2006;131:165-178.
22. Liu ZX Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 2004;127:1760-1774.
23. Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006;116:984-995.
24. Jorquera R, Tanguay RM. Cyclin B-dependent kinase and caspase-1 activation precedes mirochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J 1999; 13:2284-2298.
25. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.
26. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001;10: 1741-1752.
27. Zerbini C, Weinberg DS, Hollister KA, Perez AAR. DNA ploidy abnormalities in the liver of children with hereditary tyrosinemia type I. Correlation with histopathologic features. Am J Pathol 1992;140:1111-1119.
28. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M, Wagner EF. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003;112:181-192.
29. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-416.
30. Plentz RR, Park YN, Lechel A, Kim H, Nellessen F, Langkopf BH, et al. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. HEPATOLOGY 2007;45:968-976.